Photo of Paolo Tarantino taken from Twitter
Feb 8, 2024, 05:08
Paolo Tarantino: From no anti-HER2 drugs to a plethora of emerging options
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on Twitter/X:
“From no anti-HER2 drugs to a plethora of emerging options: promising days for targeting HER2+ colorectal cancer with TKIs, mAbs and ADCs. Check out our review on HER2+ CRC, just out in the first issue of ESMO-GI!”
View additional information.
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 21:37
Nov 15, 2024, 21:26
Nov 15, 2024, 21:09
Nov 15, 2024, 21:05
Nov 15, 2024, 21:03
Nov 15, 2024, 21:02
Nov 15, 2024, 20:28
Nov 15, 2024, 19:31
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45